Janssen Search
Search results
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
Sep 14, 2024 Spain Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT ® beyond lung cancer BARCELONA, September 14, 2024 – Johnson & Johnson ...
Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma
Dec 11, 2023 United States Oral presentations at the 2023 ASH Annual Meeting include patient-reported outcomes from the CARTITUDE-4 study and longer-term efficacy and safety data from CARTITUDE-2 study cohorts A and B, show the promise of CARVYKTI ® in ...
Our Fight Against Alzheimer’s
Our Fight Against Alzheimer’s September is World Alzheimer’s Month, a tradition that began in 2012 to draw attention to this devastating brain disease. It is easy to get discouraged about Alzheimer’s. Worldwide, nearly 44 million people have Alzheimer’s ...
Facing the alarming truth about AMR
Facing the alarming truth about AMR 3D- render of a germ bacteria under a microscope My journey as a scientist was born out of a lifelong fascination with bacteria, their biology, and their biochemistry as the smallest and earliest forms of life on earth. ...
Our Vision to Eliminate Prostate Cancer through a Multi-Pronged Approach
Our Vision to Eliminate Prostate Cancer through a Multi-Pronged Approach Prostate cancer is the second most common cancer and the fourth leading cause of cancer death in men worldwide, with an incidence of approximately 1.4 million and mortality of ...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
Jun 03, 2024 73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy 1 CHICAGO (June 3, 2024) – Johnson & Johnson ...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
Sep 08, 2024 United States New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT ® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy Results from an interim analysis featured ...
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
Sep 10, 2024 United States Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ®, a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, CA, September 10, ...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
Sep 14, 2024 Spain Post-progression outcomes showed significant and sustained improvement for RYBREVANT ® plus standard of care versus chemotherapy alone BARCELONA, September 14, 2024 – Johnson & Johnson (NYSE:JNJ) today announced updated results from ...
Science and Art Help End Stigma About Mental Illness
Science and Art Help End Stigma About Mental Illness Jun 26, 2018 Globally, one person in four will develop a mental or neurological disorder at some point in his or her life. 1 Despite such a high prevalence, stigma – shame or disgrace – about mental ...